痴呆症药物临床试验中的客观心理测量测试。来自痴呆症药物指南协调国际工作组的立场文件。 - Suppr

Suppr

超能文献

Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

作者信息

Ferris S H, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H, Geldmacher D, Bodick N

机构信息

NYU Medical Center, New York, USA.

出版信息

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:34-8.

PMID:9305514

Abstract

摘要

相似文献

Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:34-8.

Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:61-4.

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:6-7.

Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:22-5.

Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:54-5.

Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:46-9.

Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:26-8.

Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:19-21.

Information technology and the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:29-32.

Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:39-45.

引用本文的文献

Further validation of the THINC-it tool and extension of the normative data set in a study of n = 10.019 typical controls.

Int J Methods Psychiatr Res. 2022 Dec;31(4):e1922. doi: 10.1002/mpr.1922. Epub 2022 Jun 24.

Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.

Alzheimers Res Ther. 2018 Jun 29;10(1):61. doi: 10.1186/s13195-018-0386-7.

Which Cognitive Domains are Improved by Treatment with Vortioxetine?

Int J Neuropsychopharmacol. 2016 May 26;19(10):pyw054. doi: 10.1093/ijnp/pyw054.

Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research.

Alzheimers Res Ther. 2015 Mar 18;7(1):31. doi: 10.1186/s13195-015-0113-6. eCollection 2015.

Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity.

Alzheimers Res Ther. 2014 Aug 29;6(5):58. doi: 10.1186/s13195-014-0058-1. eCollection 2014.

The value of assessing cognitive function in drug development.

Dialogues Clin Neurosci. 2000 Sep;2(3):183-202. doi: 10.31887/DCNS.2000.2.3/kwesnes.

The evaluation of cognitive function in the dementias: methodological and regulatory considerations.

Dialogues Clin Neurosci. 2003 Mar;5(1):77-88. doi: 10.31887/DCNS.2003.5.1/kwesnes.

Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial.

J Nutr Health Aging. 2011 Aug;15(8):720-4. doi: 10.1007/s12603-011-0105-6.

Computerized neurocognitive testing and its potential for modern psychiatry.

Psychiatry (Edgmont). 2004 Sep;1(2):29-36.

A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact.

Pharmacoeconomics. 1998 Nov;14(5):499-530. doi: 10.2165/00019053-199814050-00004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验